Acacia Research (ACTG), Biomet Enter Patent Settlement, License
Get Alerts ACTG Hot Sheet
Price: $4.37 -0.91%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.5%
Revenue Growth %: -2.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.5%
Revenue Growth %: -2.4%
Join SI Premium – FREE
Acacia Research Corporation (Nasdaq: ACTG) announced today that its Bonutti Skeletal Innovations LLC subsidiary has entered into a settlement and patent license agreement with Biomet, Inc., Biomet Sports Medicine, LLC, Biomet Manufacturing, LLC (formerly doing business as Biomet Manufacturing Corp.) The agreement resolves litigation pertaining to suture anchors and platelet concentration that was pending in the United States District Court for the Northern District of Indiana.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GCM Grosvenor adds two hires to its Frankfurt office
- University of Phoenix partners with OpenAI on AI learning tools
- SST VI to acquire SSGT III in all-stock merger valued at $1.2B
Create E-mail Alert Related Categories
Corporate News, Life EnjoyedSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share